Biotech Holds Up Better Than SPY and QQQ; Hims Results and Summit's FDA Date in Focus
Healthcare stocks weathered the market selloff better than major indexes. This week's focus is earnings from Hims & Hers, TG Therapeutics and Teva, plus Summit's FDA date.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Stocktwits, healthcare stocks held up far better than the major benchmarks during last week's selloff. Three groups of shares slipped 0.04%, fell 1.8% and lost 2.4%, while the SPDR S&P 500 ETF Trust (SPY) dropped 2.7% and the Invesco QQQ Trust (QQQ) fell nearly 5%.
Company reports dominate this week. Hims & Hers reports after Monday's close, and investors will watch its new deal with Eli Lilly that gives patients access to Zepbound and the Foundayo pill. TG Therapeutics also reports on Monday, while Scholar Rock and Liquidia report on Tuesday. Teva holds its R&D Day on Wednesday, and Ascendis and Arrowhead report on Thursday.
Summit Therapeutics faces a closely watched FDA target date on Saturday, November 14, for ivonescimab plus chemotherapy in EGFR-mutated lung cancer.
why it matters
For markets, the point is that healthcare has held up better than tech-heavy indexes, so investors are temporarily favoring defensive names. Earnings and regulatory decisions tend to move individual biotech stocks more than the broader indexes.
market impact
Biotech stocks: relative resilience during the market selloff; earnings and FDA decisions set sentiment for individual names
tags
instruments
on polymarket
sources
- Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘ — Stocktwits, 9 November 2026 at 01:16 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗